TY - JOUR
T1 - Antimicrobial resistance in the Bacteroides fragilis group in faecal microbiota from healthy Danish children
AU - Sydenham, Thomas Vognbjerg
AU - Jensen, Betina Hebbelstrup
AU - Petersen, Andreas Munk
AU - Krogfelt, Karen Angeliki
AU - Justesen, Ulrik Stenz
N1 - Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - The Bacteroides fragilis group constitute a significant portion of the human gut microbiota and comprise a major proportion of anaerobic bacteria isolated in human infections. We established a baseline of antimicrobial susceptibility rates in the B. fragilis group in the intestinal tract of relatively antibiotic-naive healthy Danish children. From 174 faecal samples collected from children attending day care, 359 non-duplicate isolates were screened for antimicrobial susceptibility. Of these, 0.0%, 1.9%, 5.0% and 21.2% of isolates were intermediate-susceptible or resistant to metronidazole, meropenem, piperacillin/tazobactam and clindamycin, respectively. Eighteen additional studies reporting susceptibility rates in the B. fragilis group bacteria were identified by conducting a literature search. Heterogeneity among results from studies of B. fragilis group antimicrobial susceptibility rates in faecal microbiota exists.
AB - The Bacteroides fragilis group constitute a significant portion of the human gut microbiota and comprise a major proportion of anaerobic bacteria isolated in human infections. We established a baseline of antimicrobial susceptibility rates in the B. fragilis group in the intestinal tract of relatively antibiotic-naive healthy Danish children. From 174 faecal samples collected from children attending day care, 359 non-duplicate isolates were screened for antimicrobial susceptibility. Of these, 0.0%, 1.9%, 5.0% and 21.2% of isolates were intermediate-susceptible or resistant to metronidazole, meropenem, piperacillin/tazobactam and clindamycin, respectively. Eighteen additional studies reporting susceptibility rates in the B. fragilis group bacteria were identified by conducting a literature search. Heterogeneity among results from studies of B. fragilis group antimicrobial susceptibility rates in faecal microbiota exists.
KW - Anti-Bacterial Agents/therapeutic use
KW - Bacteroides Infections/drug therapy
KW - Bacteroides fragilis/drug effects
KW - Child
KW - Clindamycin/therapeutic use
KW - Denmark
KW - Drug Resistance, Bacterial
KW - Feces/microbiology
KW - Humans
KW - Metronidazole/therapeutic use
KW - Microbial Sensitivity Tests
KW - Microbiota/drug effects
KW - Penicillanic Acid/analogs & derivatives
KW - Piperacillin/therapeutic use
KW - Surveys and Questionnaires
KW - Thienamycins/therapeutic use
U2 - 10.1016/j.ijantimicag.2017.01.011
DO - 10.1016/j.ijantimicag.2017.01.011
M3 - Journal article
C2 - 28366659
SN - 0924-8579
VL - 49
SP - 573
EP - 578
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 5
ER -
